The rising cost of healthcare has been a cause of concern around the globe. The global economic crisis has seen governments such as the US and Japan attempting to minimise the cost of state-funded healthcare.
The increased prevalence of cardiovascular disorders, metabolic diseases, cancer, etc coupled with the emergence of more virulent forms of existing diseases poses a challenge for current medical therapies.
India is already seen as the world’s low-cost pharmacy as far as conventional therapies are concerned. And the recent economic and epidemiological changes present a lucrative opportunity for the Indian biotech industry to replicate this success in the